



#6.

SEQUENCE LISTING

<110> GENZYME CORPORATION
Scaria, Abraham
Wadsworth, Samuel C.

<120> METHODS FOR TREATING BLOOD COAGULATION DISORDERS

<130> 5046US

<140> US 10/057,620
<141> 2001-10-25

<150> PCT/US01/51391
<151> 2001-10-25

<150> US 60/307,492
<151> 2001-07-24

<150> US 60/243,046
<151> 2000-10-25

<160> 20

<170> PatentIn version 3.2

<210> 1
<211> 8
<212> PRT
<213> Homo sapiens

<400> 1

Ser Lys Pro Gln Gly Arg Ile Val
1 5

<210> 2
<211> 8
<212> PRT
<213> Homo sapiens

<400> 2

Ser Lys Arg Gln Lys Arg Ile Val
1 5

<210> 3
<211> 13
<212> PRT
<213> Homo sapiens

<400> 3

Ser Lys Pro Gln Gly Arg Arg Arg Arg Ala Asn Ile Val
1 5 10

<210> 4
<211> 12
<212> PRT
<213> Homo sapiens

<400> 4

Ser Lys Pro Gln Gly Arg Arg Arg Arg Ser Ile Val
1 5 10

<210> 5
<211> 9
<212> PRT
<213> Homo sapiens

<400> 5

Ser Lys Arg Gln Lys Arg Ala Ile Val
1 5

<210> 6
<211> 11
<212> PRT
<213> Homo sapiens

<400> 6

Ser Lys Arg Gln Arg Arg Ala Asn Gly Gly Lys
1 5 10

<210> 7
<211> 8
<212> PRT
<213> Homo sapiens

<400> 7

Arg Lys Arg Gln Lys Arg Ile Val
1 5

<210> 8
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = Any amino acid residue

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = Any amino acid residue

<400> 8

Arg Xaa Xaa Arg
1

<210> 9
<211> 8
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> X = Arg or Lys

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> X = Arg or Lys

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = Leu or Val or Phe

<400> 9

Xaa Lys Xaa Gln Xaa Arg Ile Val
1 5

<210> 10
<211> 4
<212> PRT
<213> Homo sapiens

<400> 10

Arg Gln Lys Arg
1

<210> 11
<211> 4
<212> PRT
<213> Homo sapiens

<400> 11

Pro Gln Gly Arg
1

<210> 12
<211> 39
<212> DNA
<213> Artificial

<220>
<223> Oligonucleotide primer

<400> 12
ctagcctagg ccaccatggg ctcccaggcc ctcaggctc

39

<210> 13
<211> 34
<212> DNA
<213> Artificial

<220>
<223> Oligonucleotide primer

<400> 13

ccttaattaa ctagggaaat ggggctcgca ggag

34

<210> 14
<211> 21
<212> DNA
<213> Artificial

<220>
<223> Oligonucleotide primer

<400> 14
gctagcctat cggccttggg g

21

<210> 15
<211> 36
<212> DNA
<213> Artificial

<220>
<223> Oligonucleotide primer

<400> 15
tgcaccggcg ccggcgcat tgggggggca aggtgt

36

<210> 16
<211> 33
<212> DNA
<213> Artificial

<220>
<223> Oligonucleotide primer

<400> 16
agcaaacgcc aaaagcgaat tgtggggggc aag

33

<210> 17
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> X = Any amino acid residue

<400> 17

Arg Xaa Lys Arg
1

<210> 18
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (2)..(2)

<223> X = Any amino acid residue

<400> 18

Arg Xaa Arg Arg

1

<210> 19

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X = Arg or Lys

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = Any amino acid residue

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = Any amino acid residue

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X = Arg or Lys

<400> 19

Xaa Xaa Arg Xaa Xaa Arg

1

5

<210> 20

<211> 6

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> X = Arg or Lys

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> X = Any amino acid residue

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> X = Arg or Lys

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> X = Any amino acid residue

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> X = Leu or Val or Phe

<400> 20

Xaa Xaa Xaa Xaa Xaa Glx
1 5